Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameZhongzhipharm
Stock Code03737
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們主要於中國從事製藥及於中國廣東省中山營運連鎖藥店,開發、製造及出售中成藥及飲片(包括傳統飲片及新型飲片兩者),產品以核心品牌「中智」、「六棉牌」及「草晶華」出售。
Listing Date2015-07-13
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省中山市火炬開發區康泰路南3號
Business Address (Hong Kong)香港中環德輔道中141號中保集團大廈2102–2103室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitezeus.cn
Share Registrar联合
Registrar Contact(852)2849 3399
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 2.46 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2015-06-30 to 2015-07-06
Global Offering Shares200,000,000 shares
HK Public Offer Shares (Initial)20,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)180,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO800,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share5.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 492,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 625.2M
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +1402%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣86.7百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201220132014
Revenue 410,052482,805595,565
Cost of sales -221,365-243,430-275,290
Gross profit 188,687239,375320,275
Other income and gains, net 7,3705,3836,528
Selling and distribution expenses -121,904-142,326-148,747
Administrative expenses -35,258-38,881-50,196
Operating profit 27,74348,187115,812
Net finance costs -4,294-1,384-1,002
Profit before tax 23,44946,803114,810
Income tax expense -6,195-9,165-28,122
Profit for the year 17,25437,63886,688
Profit attributable to owners 17,25437,63886,688
Balance Sheet
Item 201220132014
Cash and cash equivalents 25,04429,07758,004
Trade and bills receivables 26,80628,80435,489
Inventories 81,241108,94088,471
Total current assets 148,181200,039190,377
Total assets 239,621298,874297,924
Total current liabilities 139,537157,766163,631
Total liabilities 147,050168,664177,027
Total equity 92,571130,210120,897
Equity attributable to owners 92,571130,210120,897
Interest-bearing borrowings 25,00016,00015,000
Cash Flow Statement
Item 201220132014
Net cash from operating activities 55,53944,983121,637
Net cash from investing activities -5,495-30,5675,293
Net cash from financing activities -44,010-10,384-98,002
Net increase in cash 6,0344,03228,928
Depreciation of PP&E 11,56610,70112,028
Amortisation of intangible assets 264285224
Purchase of PP&E -10,124-16,573-20,631
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.39
First Day OpenHK$ 2.25
First Day Change-2.85%
First Day Volume34880000.0
First Day Turnover80799800.0
Use of Proceeds
1、約136,000,000港元(約30%)將用于擴充公司在廣東省的連鎖藥店; 2、約90,500,000港元(約20%)將用于擴充公司的分銷網絡; 3、約90,500,000港元(約20%)將用于繼續進行公司的研發活動,其集中于新型飲片生產技術的應用及加強我們有關該方面的產品組合,以支持公司的長遠增長; 4、約90,500,000港元(約20%)將用作購買制造新型飲片之機器,并升級公司現有的生產設施; 5、約45,400,000港元(約10%)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
Guosen Securities (HK) Capital Company Limited CE AUX600
Overall Coordinators (2)
Guosen Securities (HK) Capital Company Limited CE AUX600 农银国际融资有限公司 CE AWL249
Joint Bookrunners (3)
Guosen Securities (HK) Capital Company Limited CE AUX600 农银国际融资有限公司 CE AWL249 招银国际融资有限公司 CE AVM940
Joint Lead Managers (3)
Guosen Securities (HK) Capital Company Limited CE AUX600 农银国际融资有限公司 CE AWL249 招银国际融资有限公司 CE AVM940

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 中融国际信托有限公司 116,294,040 HKD — 5.91% — 6 months 2016-01-13

Directors & Management

PositionChinese nameEnglish Name
Chairman賴智填—
Company Secretary周鳳玲—
No director data available.

Major Shareholders

Major Shareholders & Holdings顯智持有483,120,000股(60.39%)、智力持有42,240,000股(5.28%);賴先生及賴太太被視為控股股東,合共持有本公司上市後已發行股本約65.67%。
About this page

This page shows Zhongzhipharm (03737) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect